Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Publication | Open Access

DOI Full Paper Access

170

Citations

References

2022

Year

Alasdair Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K. Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee,

The Lancet Infectious Diseases